THERAPY DOSSIER · th-a767bc230f80

GFP-labelled rat bone marrow mesenchymal stem cell aggregate, compared with equal numbers of dissociated BMMSCs

Biologic · CLASS-LEVEL match. No human trial administers GFP-labelled cells or compares aggregated versus dissociated BMMSC; GFP labelling is a preclinical tracking tool. Recorded trials are unmodified autologous or allogeneic bone marrow MSC preparations, all delivered as dissociated suspensions.

Non-drug Suggest a correction

Evidence & regulatory context

Mechanism: CLASS-LEVEL match. No human trial administers GFP-labelled cells or compares aggregated versus dissociated BMMSC; GFP labelling is a preclinical tracking tool. Recorded trials are unmodified autologous or allogeneic bone marrow MSC preparations, all delivered as dissociated suspensions.
Target: Not recorded
Injury models: Wound
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 5

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT02334878 ↗PHASE3completed

Autologous bone marrow-derived mesenchymal stem cells versus tension-free vaginal tape for female stress urinary incontinence

Urinary Incontinence, Stress

Enrolment: 50 · Results not recorded

NCT01730547 ↗PHASE1/PHASE2completed

Autologous mesenchymal stem cells for the therapy of multiple sclerosis

Multiple Sclerosis

Enrolment: 2 · Results not recorded

NCT00883727 ↗PHASE1/PHASE2completed

Intravenous ex vivo cultured adult allogeneic mesenchymal stem cells in ST-elevation acute myocardial infarction

Myocardial Infarction

Enrolment: 20 · Results not recorded

NCT04519684 ↗PHASE1/PHASE2terminated

Allogeneic bone marrow derived mesenchymal stem cells for ileal anal anastomosis and ileal pouch fistulas in Crohn's disease of the pouch

Ileal Pouch · Crohn Disease

Enrolment: 24 · Results not recorded

NCT01210950 ↗PHASE1completed

Autologous transplantation of bone marrow derived mesenchymal stem cells in distraction osteogenesis in patients with limb-length discrepancy

Leg Length Inequality

Enrolment: 6 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26594024 ↗2015Reported benefit

Bone marrow mesenchymal stem cell aggregate: an optimal cell therapy for full-layer cutaneous wound vascularization and regeneration.

RatWoundSprague-Dawley hosts with GFP-transgenic Sprague-Dawley donorsFemale hostsn = 96 female host rats in 6 groups, 6 excluded for acute infec…Aggregate laid on the wound bed under SIS membrane and Tegaderm; topical arm subcutaneous at four sites 3 mm from the wound rim; intravenous arm via the caudal veinOne aggregate per wound containing on average 1.35 (SD 0.07…Immediately after wounding, within 30 s of injury

Model: Acute full-thickness (full-layer) excisional cutaneous wound, 2 cm diameter, on the dorsum with panniculus carnosus removed

Aggregate transplantation gave the smallest residual wound area at 4 weeks (6.43% of original versus 13.12% topical and 13.10% intravenous), the highest capillary density and more regular collagen, together with a shorter inflammatory phase and greater GFP-positive cell engraftment. All three cell-…

Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…